Exactly - there is emotional involvement from all sides here. The difference is that the company who has the better product trades at a 99% discount to the bone marrow joint. Yes, Bone-marrow R Us has approval in a small, niche indication and Cynata doesn't. But they also traded significantly higher than where Cynata currently does prior to approval.
Emotions aside, these things will mean-revert over time. The three clinical trial readouts over the next 12-15 months will encourage that reversion (commercial deals even better!).
CYP Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)